UP!

MR $5.36

MR target price
5.36
0
0
Mindray Medical International Limited
Type
Public (NYSE: MR)
Industry Medical Devices
Founded Shenzhen, China (1991)
Headquarters Shenzhen, China
Key people
President & Co-CEO
LI Xiting, Co-CEO
CHENG Minghe
Products Patient Monitors, ECG, Pulse Oxymeters, Telemetery, Ultrasound Systems, Anesthesia Delivery Systems, Hematology Analyzers, Chemistry Analyzers, Regents, Veterinary Equipment
Revenue Increase $1.3 billion USD (2014)
Net income
Increase $193 million
Number of employees
about 10,000 (2014)
Website Mindray
Datascope Patient Monitors
Footnotes / references
U.S. Food and Drug Administration registration numbers 3007222337, 3004365718, and 2221819

Mindray Medical International Limited is China's largest medical equipment manufacturer, developing, manufacturing, and marketing a variety of medical devices, equipment and accessories for both human and veterinary use. The company is currently organized into three key business lines: Patient Monitoring & Life Support, In-Vitro Diagnostic Products, and Medical Imaging Systems.

Headquartered in Shenzhen, China, Mindray possesses a sound R&D, marketing and service network with 41 subsidiaries and branch offices in 31 countries in North and Latin America, Europe, Africa and Asia-Pacific, as well as 32 branch offices in China. To date, Mindray has around 8200 employees around the world. Its North American headquarters are located in Mahwah, New Jersey.

The Patient Monitoring & Life Support division develops and manufactures multi-parameter patient monitors, biotelemetry systems, Anesthesia Delivery Systems, Defibrillators, ECG machines, pulse oxymeters, hospital beds, mounting systems and IT solutions for customers worldwide. In 2008, Mindray purchased the Patient Monitoring division of Datascope Corporation for $209 million to expand their presence outside of China.

The In-Vitro Diagnostic division provides data and analysis on blood, urine, and other bodily fluid samples for clinical diagnosis and treatment. This segment offers a range of semi-automated and fully automated diagnostic laboratory instruments for laboratories, clinics, and hospitals. Its products include hematology analyzers, biochemistry analyzers, reagents, a microplate reader and a microplate washer.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2020 2020-11-05 0.00 0.00
Q2 2020 2020-08-06 -0.57 -1.88
Q1 2020 2020-05-07 0.03 0.30
Q4 2019 2020-03-05 0.89 0.39
Q3 2019 2019-11-07 0.54 0.15
Q2 2019 2019-08-06 0.41 0.69
Q1 2019 2019-05-07 0.70 -0.54
Q4 2018 2019-03-12 1.16 1.80
Q3 2018 2018-10-31 0.60 0.15

Ratings

2015-11-13 Reiterated Rating Standpoint Research Buy to Hold
2015-10-23 Downgrade Deutsche Bank Buy to Hold $30.00 to $27.00
2015-10-23 Downgrade Deutsche Bank AG Buy to Hold $30.00 to $27.00
2015-06-05 Upgrade JMP Securities Underperform to Market Perform $30.00
2015-05-22 Reiterated Rating JMP Securities Underperform $22.00 to $20.00
2015-03-11 Lower Price Target JMP Securities Market Underperform $23.00 to $22.00
2015-03-11 Downgrade Credit Suisse Neutral to Underperform
2015-03-11 Downgrade Credit Suisse Group AG Neutral to Underperform
2015-03-06 Set Price Target Deutsche Bank Buy $34.00
2014-12-22 Initiated Coverage Standpoint Research Buy $36.00
2014-12-12 Downgrade Morgan Stanley Equal Weight to Underweight $37.00 to $28.00
2014-05-22 Lower Price Target Jefferies Group Hold $36.00 to $32.00
2014-05-07 Downgrade Bank of America Buy to Neutral
2014-05-06 Reiterated Rating Morgan Stanley In-Line
2014-04-24 Upgrade Credit Suisse Underperform to Neutral
2014-04-14 Downgrade Morgan Stanley Overweight to Equal Weight $44.00 to $37.00
2014-04-07 Downgrade Goldman Sachs Buy to Neutral $45.50 to $31.20
2014-03-04 Lower Price Target Oppenheimer Outperform $50.00 to $42.00
2013-12-13 Upgrade Bank of America Buy
2013-11-06 Lower Price Target Jefferies Group Hold $43.00 to $36.00
2013-11-04 Initiated Coverage Credit Suisse Underperform
2010-08-11 Downgrade Brean Murray Buy to Hold
2009-12-11 Initiated Citigroup Buy $36
2009-08-25 Initiated Soleil Buy
2009-07-27 Initiated Susquehanna Financial Positive
2008-12-18 Initiated Maxim Group Buy $35
2008-12-02 Reiterated Credit Suisse Outperform $41 to $36
2008-02-21 Initiated Citigroup Buy
2007-11-21 Initiated Bear Stearns Outperform
2007-11-12 Upgrade UBS Neutral to Buy
2007-11-02 Reiterated Brean Murray Buy $39 to $50
2007-08-07 Reiterated Brean Murray Buy $36 to $39
2015-11-13 Reiterated Rating Standpoint Research Buy to Hold
2015-10-23 Downgrade Deutsche Bank Buy to Hold $30.00 to $27.00
2015-10-23 Downgrade Deutsche Bank AG Buy to Hold $30.00 to $27.00
2015-06-05 Upgrade JMP Securities Underperform to Market Perform $30.00
2015-05-22 Reiterated Rating JMP Securities Underperform $22.00 to $20.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks